HOME: ABSA in Action: Reviews & Comments

Reviews & Comments

ABSA Comments on the proposed exemption of well-characterized transgenic animals from the NIH Guidelines.
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 10 August, 2010

ABSA Comments on the NIH Guidelines for Research with Recombinant DNA
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 31 May, 2010

ABSA Comments on the Screening Framework Guidance for Synthetic Double Stranded DNA Providers
a letter written by Benjamin Fontes, MPH, CBSP, President, ABSA, 21 January, 2010

ABSA Comments on the proposal to classify SARS as a Select Agent
a letter written by Robert Ellis, PhD, CBSP, President, ABSA, 11 September, 2009

Open Letter from the ABSA Legislative Committee(PDF 100KB); July 22, 2009

ABSA Comments to the Working Group on Strengthening the Biosecurity of the United States Following the Public Meeting May 13-14, 2009(PDF 52KB)

ABSA response to the NIH Guidelines for Research Involving Recombinant DNA Molecules(PDF 56KB); May 28, 2009

ABSA Comments on the Select Agent Program & Biosecurities Improvement Act(PDF 32KB); March 28, 2008

ABSA Position Paper on Accreditation of High Containment Laboratories(PDF 24KB); April 18, 2008

ABSA Comments on the Proposed Framework for the Oversight of Dual Use(PDF 92KB); Nov. 19, 2007

ABSA Comments Regarding the 5th Edition of the Biosafety in Microbiological and Biomedical Laboratories (BMBL). (PDF 108KB)
a letter written by Bill Homovec, MPH, CBSP, Chair and Co Team Leader, ABSA Technical and Regulatory Review Committee, May 2, 2007

ABSA Comments Regarding the Draft Pandemic Influenza Preparedness and Response Plan
a letter written by Elizabeth Gilman Duane, MS, RBP, CBSP, President, ABSA, October 25, 2004

ABSA Comments Regarding Operational Issues of the CDC Select Agent Program
a letter written by Stefan Wagener, Ph.D., RBP, CBSP, President, ABSA, 6 April 2004
          CDC Response to ABSA Comments Regarding the CDC Select Agent Program

ABSA Comments Regarding National Committee of Clinical Laboratory Standard, NM29-3A, Protection of Laboratory Workers from Occupationally-Acquired Infections
a letter written by Stefan Wagener, Ph.D., RBP, CBSP, President, ABSA, 5 April 2004

ABSA Comments on CDC Select Agent Rule
a letter written by Barbara Johnson, Ph.D., RBP, President, ABSA, 5 February 2003

Letter from the Biosecurity Task Force(PDF 496KB)
a letter written by Barbara Johnson, Ph.D., RBP, President-Elect, ABSA, and the ABSA Biosecurity Task Force, June 2002

ABSA Comments on Health Canada Revisions, American Biological Safety Association
a letter written by Debra Hunt, DrPh, RBP, CBSP, Past-President, ABSA, 4 March 2002

CDC - "Draft Guideline for Hand Hygiene in Healthcare Settings"
a letter written by Maureen Best, President, American Biological Safety Association, 7 December 2001

NIH Guidelines for Research Involving Recombinant DNA Molecules
a letter written by Debra Hunt, DrPH, RBP, CBSP (ABSA), President, American Biological Safety Association, 10 September 2001

NCCLS - Protection of Laboratory Workers from Occupationally-Acquired Infections
a letter written by Debra Hunt, MT (ASCP), DrPH, CBSP (ABSA), President, American Biological Safety Association, 29 August 2001

Response to: Hazardous Materials: Revision to Standards for Infectious Substances and Genetically Modified Microorganisms
a letter written by Debra Hunt, Dr.PH, RBP, CBSP (ABSA), President, American Biological Safety Association, 18 April 2001

HIV Prevention Plan Comments
a letter written by Debra Hunt, Dr.PH, RBP, CBSP, President, American Biological Safety Association, 5 February 2001

ABSA Response To: NIH Guidelines for Research Involving Recombinant DNA Molecules
a letter written by Debra Hunt, Dr.PH, RBP, CBSP (ABSA), President, American Biological Safety Association, February 2001

Arthropod Containment Guidelines (ACG)
a letter written by Debra L. Hunt, Dr.PH , RBP, CBSP (ABSA), President, American Biological Safety Association, February 2001

ABSA's Response to the "Needlestick Safety Prevention Act"
a letter written by John H. Keene, Dr.PH, CBSP (ABSA), President, American Biological Safety Association, 17 October 2000

Institute of Medicine Response - Response to the OSHA TB Standard
a letter written by John H. Keene, Dr.PH, CBSP (ABSA) President, American Biological Safety Association, 29 July 2000

ABSA comments on: 42 CFR Part 72 "Packaging and Handling of Infectious Substances and Select Agents" (CDC NPRM, 1999)
a letter written by John H. Keene, Dr.PH, CBSP (ABSA), President, American Biological Safety Association, 21 December 1999


Calendar Members Only